Both Fidaxomicin and Vancomycin Inhibit Outgrowth of Clostridium difficile Spores Academic Article uri icon

abstract

  • Fidaxomicin (FDX) is approved to treat Clostridium difficile-associated diarrhea and is superior to vancomycin in providing a sustained clinical response (cure without recurrence in the subsequent 25 days). The mechanism(s) behind the low recurrence rate of FDX-treated patients could be multifactorial. Here, we tested effects of FDX, its metabolite OP-1118, and vancomycin on spore germination and determined that none affected the initiation of spore germination but all inhibited outgrowth of vegetative cells from germinated spores.

altmetric score

  • 3.75

author list (cited authors)

  • Allen, C. A., Babakhani, F., Sears, P., Nguyen, L. y., & Sorg, J. A.

citation count

  • 45

publication date

  • November 2012